Full Press Release Details
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc.(NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are theOpera Phenix OptIQ™ high-content screening system, theEnVision Nexus™ One multimode plate reader, and theAssayMate™ workstation, alongside other recently introduced solutions spanning sample preparation, screening, advanced imaging, and lab automation.
Revvity, Inc. announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows.
At booth #612, Revvity will showcase an expanded portfolio of integrated workflow solutions designed to support discovery programs from early screening through data-driven decision making. Solutions debuting at SLAS2026 include:
“SLAS2026 marks a key milestone for Revvity with the introduction of new platforms that support the evolving needs of discovery labs,” said Kevin Quick, vice president, platforms, Revvity. “These launches integrate automation, trusted assay technologies, and AI-driven imaging to help customers accelerate results while maintaining data quality.”
For more information on Revvity’s new product launches, demonstrations, and conference activities at SLAS2026, visit booth #612 orthis link.
For research use only. Not for use in diagnostic procedures.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Stay updated by following ourNewsroom,LinkedIn,X,YouTube,FacebookandInstagram.